Chapter 7. Management of Depressed High-Density Lipoprotein Cholesterol

  1. Peter P. Toth M.D., PH.D. Director of Preventive Cardiology Chief of Medicine Clinical Associate Professor1,2,3,4 and
  2. Kevin C. Maki PH.D. President Chief Science Officer5

Published Online: 1 OCT 2008

DOI: 10.1002/9780470696873.ch7

Practical Lipid Management: Concepts and Controversies

Practical Lipid Management: Concepts and Controversies

How to Cite

Toth, P. P. and Maki, K. C. (2008) Management of Depressed High-Density Lipoprotein Cholesterol , in Practical Lipid Management: Concepts and Controversies, John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9780470696873.ch7

Author Information

  1. 1

    Sterling Rock Falls Clinic, Ltd., USA

  2. 2

    CGH Medical Center Sterling, Illinois, USA

  3. 3

    Departments of Family and Community Medicine, University of Illinois College of Medicine Peoria, Illinois, USA

  4. 4

    Southern Illinois University School of Medicine, Springfield, Illinois, USA

  5. 5

    Provident Clinical Research & Consulting, Inc., Glen Ellyn, Illinois and Bloomington, Indiana, USA

Publication History

  1. Published Online: 1 OCT 2008
  2. Published Print: 17 OCT 2008

ISBN Information

Print ISBN: 9780470056905

Online ISBN: 9780470696873

SEARCH

Keywords:

  • HDL cholesterol;
  • Cooperative Lipoprotein Phenotyping Study (CLPS);
  • National Cholesterol Education Program (NCEP);
  • HDL antiatherogenic effects;
  • very low-density lipoprotein (VLDL) and LDL;
  • scavenger receptor B-I (SR-BI);
  • HDL and insulin resistance;
  • low HDL pharmacologic management;
  • fibrates and triglyceride metabolism

Summary

This chapter contains sections titled:

  • The Relationship between HDL and Risk For CVD

  • Prevalence of Low HDL-C

  • Goals for HDL Treatment

  • Antiatherogenic Effects of HDL

  • HDL and Insulin Resistance

  • Effects of Lifestyle Modification on Serum HDL

  • Pharmacologic Management of Low HDL

  • Controversy: Do we Need HDL Treatment Goals?